Achyut Healthcare Limited announced its unaudited financial results for the quarter ended December 31, 2025, along with several strategic corporate developments approved by its Board of Directors on January 21, 2026. The pharmaceutical trading company reported mixed quarterly performance while outlining ambitious expansion plans through capital restructuring and fundraising initiatives.

Financial Performance for Q3FY26

The company's financial results for the quarter ended December 31, 2025, showed total income of ₹161.12 lakhs, comprising revenue from operations of ₹156.96 lakhs and other income of ₹4.16 lakhs. Net profit for the quarter stood at ₹0.43 lakhs after accounting for total expenses of ₹160.23 lakhs and tax expenses of ₹0.46 lakhs.

For the nine months ended December 31, 2025, the company achieved total income of ₹744.59 lakhs with net profit of ₹23.73 lakhs, compared to ₹286.91 lakhs income and ₹38.59 lakhs profit in the corresponding period of the previous year.

Preferential Issue and Capital Expansion

The Board approved a significant preferential issue of up to 58 lakh equity shares of ₹1 face value each at an issue price of ₹6 per share, including a premium of ₹5 per share. The total issue size amounts to ₹3.48 crores and will be allocated to both promoter and non-promoter categories.

The preferential allotment includes allocations to promoter entities such as Akshit Mahendra Raycha (8 lakh shares), Mahendra C. Raycha HUF (8 lakh shares), and non-promoter investors including Strikar Lifescience LLP (18 lakh shares) and individual investors Dhavalkumar and Mayankbhai Ruparelia (10 lakh shares each).

Authorized Capital Enhancement

To facilitate future fundraising activities, the Board approved increasing the company's authorized capital from ₹24 crores to ₹26 crores. This enhancement will require corresponding amendments to Clause V of the Memorandum of Association, subject to shareholder approval. The revised authorized capital will comprise 26 crore equity shares of ₹1 each.

Corporate Developments

The company announced the relocation of its registered office within Ahmedabad city limits from 610 Colonade, Iscon-Ambali Road to 504, Iscon Elegance, Circle P, S.G. Highway, Ahmedabad-380015. The Board stated this move will facilitate expansion of operations, provide larger workspace, and better accommodate growing administrative requirements.

Platform Migration and Compliance

Achyut Healthcare successfully migrated from BSE SME platform to BSE Main Board, with equity shares commencing trading on the main board from January 2, 2026. Consequently, the company adopted Indian Accounting Standards (Ind AS) effective April 1, 2025, with the transition date being April 1, 2024. The current quarterly results represent the third unaudited quarterly financial results prepared under Ind AS framework.

The Board has scheduled an Extraordinary General Meeting on February 19, 2026, to seek shareholder approval for the preferential issue, authorized capital increase, and related amendments to the Memorandum of Association.

Achyut Healthcare Limited has achieved a significant corporate milestone by receiving approval from BSE Limited for the migration of its equity shares from the BSE SME platform to the BSE Main Board Platform. This development marks an important step in the company's evolution and provides enhanced market access for investors.

Migration Approval Details

The pharmaceutical company received the formal approval through BSE Limited's communication dated January 01, 2026. The approval process was completed under the regulatory framework governing platform migrations for listed companies.

Trading Commencement

The company's equity shares will be effectively listed and traded on the BSE Main Board Platform starting from Friday, January 02, 2026. This transition represents the culmination of the migration process and provides investors with access to the company's shares on the main board platform.

Regulatory Compliance

Achyut Healthcare Limited has fulfilled all regulatory requirements for the migration process. The company communicated this development to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full compliance with disclosure obligations.

Company Background

Achyut Healthcare Limited operates in the pharmaceutical sector and is classified as a Small Cap company with a market capitalization of ₹133.80 crores. The company maintains its registered office in Ahmedabad, Gujarat, with additional corporate and administrative facilities in the region. The migration to the main board platform represents a significant advancement in the company's market presence and accessibility to a broader investor base.